Coronavirus Disease 2019 (COVID-19) Reinfection Rates in Malawi: A Possible Tool to Guide Vaccine Prioritisation and Immunisation Policies.

COVID-19 SARS-CoV-2 immune response immunizations reinfection vaccinations

Journal

Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355

Informations de publication

Date de publication:
30 Jun 2023
Historique:
received: 12 04 2023
revised: 19 06 2023
accepted: 26 06 2023
medline: 29 7 2023
pubmed: 29 7 2023
entrez: 29 7 2023
Statut: epublish

Résumé

As the fight against the COVID-19 pandemic continues, reports indicate that the global vaccination rate is still far below the target. Understanding the levels of reinfection may help refocus and inform policymakers on vaccination. This retrospective study in Malawi included individuals and patients who tested for COVID-19 infections via reverse transcriptase polymerase chain reaction (rt-PCR) from the data at the Public Health Institute of Malawi (PHIM). We included all data in the national line list from April 2020 to March 2022. Upon review of 47,032 records, 45,486 were included with a reported 82 (0.18) reinfection representing a rate of 0.55 (95% CI: 0.44-0.68) per 100,000 person-days of follow-up. Most reinfections occurred in the first 90 to 200 days following the initial infection, and the median time to reinfection was 175 days (IQR: 150-314), with a range of 90-563 days. The risk of reinfection was highest in the immediate 3 to 6 months following the initial infection and declined substantially after that, and age demonstrated a significant association with reinfection. Estimating the burden of SARS-CoV-2 reinfections, a specific endurance of the immunity naturally gained, and the role played by risk factors in reinfections is relevant for identifying strategies to prioritise vaccination.

Identifiants

pubmed: 37515002
pii: vaccines11071185
doi: 10.3390/vaccines11071185
pmc: PMC10383452
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Luke International Malawi
ID : PS-IR-110001

Références

Diabetes Metab Syndr. 2021 May-Jun;15(3):1001-1006
pubmed: 33989898
PLoS Biol. 2022 Feb 10;20(2):e3001531
pubmed: 35143473
Clin Microbiol Infect. 2021 Mar;27(3):315-318
pubmed: 33285276
Nat Commun. 2021 Jun 18;12(1):3737
pubmed: 34145289
Lancet Glob Health. 2021 Jul;9(7):e905-e907
pubmed: 34090610
Clin Infect Dis. 2021 Nov 16;73(10):1882-1886
pubmed: 33718968
Rev Soc Bras Med Trop. 2021 Mar 22;54:e0002-2021
pubmed: 33759910
Front Med (Lausanne). 2021 Nov 25;8:770381
pubmed: 34901085
Epidemiol Infect. 2021 Feb 04;149:e39
pubmed: 33536108
Glob Health Res Policy. 2022 Apr 29;7(1):12
pubmed: 35488305
IJID Reg. 2022 Mar;2:25-29
pubmed: 35721435
JAMA Intern Med. 2021 Oct 1;181(10):1407-1408
pubmed: 34048531
Vaccines (Basel). 2022 Jul 06;10(7):
pubmed: 35891247
Front Public Health. 2022 May 02;10:884121
pubmed: 35586006
Lancet Respir Med. 2023 May;11(5):439-452
pubmed: 36780914
Clin Infect Dis. 2021 Jul 15;73(2):e458-e465
pubmed: 32649743
PLoS One. 2021 Jul 19;16(7):e0253621
pubmed: 34280217
Science. 2021 Feb 26;371(6532):916-921
pubmed: 33479118
Front Immunol. 2022 Oct 12;13:1015002
pubmed: 36304449
Rev Med Virol. 2022 Mar;32(2):e2271
pubmed: 34228851
Vaccines (Basel). 2022 Nov 08;10(11):
pubmed: 36366393
Eur J Clin Invest. 2021 Apr;51(4):e13520
pubmed: 33583018
J Clin Microbiol. 2021 Mar 19;59(4):
pubmed: 33361342
Rev Med Virol. 2021 Jul;31(4):e2200
pubmed: 34260777
N Engl J Med. 2021 Feb 11;384(6):533-540
pubmed: 33369366
JAMA Netw Open. 2021 Nov 1;4(11):e2132563
pubmed: 34730817
BMJ. 2020 Dec 30;371:m4961
pubmed: 33380408
Nature. 2021 Mar;591(7851):639-644
pubmed: 33461210
Clin Infect Dis. 2021 Apr 8;72(7):e192-e195
pubmed: 33161427
Lancet Reg Health Eur. 2022 Sep;20:100453
pubmed: 35791336
Lancet. 2021 Mar 27;397(10280):1204-1212
pubmed: 33743221
Immunol Rev. 2006 Jun;211:320-37
pubmed: 16824139
Lancet Glob Health. 2021 Mar;9(3):e257-e266
pubmed: 33515512
PLoS One. 2021 Jun 23;16(6):e0252617
pubmed: 34161316
Clin Microbiol Infect. 2021 Mar;27(3):331-340
pubmed: 33228974
JAMA Intern Med. 2021 May 1;181(5):672-679
pubmed: 33625463
JMIR Public Health Surveill. 2020 May 13;6(2):e19097
pubmed: 32369029

Auteurs

Master R O Chisale (MRO)

Faculty of Sciences, Technology and Innovations, Biological Sciences, Mzuzu University, P/Bag 201 Luwinga, Mzuzu, Malawi.
Research Department, Luke International, Mzuzu P.O. Box 1088, Malawi.

Frank Watson Sinyiza (FW)

Mzuzu Central Hospital, Ministry of Health, P/Bag 209 Luwinga, Mzuzu, Malawi.

Paul Uchizi Kaseka (PU)

Mzuzu Central Hospital, Ministry of Health, P/Bag 209 Luwinga, Mzuzu, Malawi.

Chikondi Sharon Chimbatata (CS)

Mzuzu Central Hospital, Ministry of Health, P/Bag 209 Luwinga, Mzuzu, Malawi.

Balwani Chingatichifwe Mbakaya (BC)

Department of Public Health, University of Livingstonia, Mzuzu 00265, Malawi.

Tsung-Shu Joseph Wu (TJ)

Research Department, Luke International, Mzuzu P.O. Box 1088, Malawi.
Overseas Department, Pingtung Christian Hospital, No. 60, Da-lien Rd., Pingtung City 900, Taiwan.

Billy Wilson Nyambalo (BW)

Public Health Institute of Malawi, Ministry of Health, Lilongwe 00265, Malawi.

Annie Chauma-Mwale (A)

Public Health Institute of Malawi, Ministry of Health, Lilongwe 00265, Malawi.

Ben Chilima (B)

Public Health Institute of Malawi, Ministry of Health, Lilongwe 00265, Malawi.

Kwong-Leung Joseph Yu (KJ)

Research Department, Luke International, Mzuzu P.O. Box 1088, Malawi.
Overseas Department, Pingtung Christian Hospital, No. 60, Da-lien Rd., Pingtung City 900, Taiwan.

Alfred Bornwell Kayira (AB)

Mzuzu Central Hospital, Ministry of Health, P/Bag 209 Luwinga, Mzuzu, Malawi.

Classifications MeSH